Mineralys Therapeutics, Inc. MLYS
We take great care to ensure that the data presented and summarized in this overview for Mineralys Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MLYS
Top Purchases
Top Sells
About MLYS
Insider Transactions at MLYS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 13
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,365
-10.9%
|
$136,380
$12.93 P/Share
|
|
Aug 12
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+5.74%
|
$6,349
$1.08 P/Share
|
|
Jul 30
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
59,925
-16.33%
|
$838,950
$14.9 P/Share
|
|
Jul 29
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
807
-0.42%
|
$11,298
$14.0 P/Share
|
|
Jul 28
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
12,946
-6.27%
|
$181,244
$14.04 P/Share
|
|
Jul 14
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,366
-10.4%
|
$159,124
$14.59 P/Share
|
|
Jul 14
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+5.49%
|
$6,349
$1.08 P/Share
|
|
Jul 11
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
10,758
-4.95%
|
$150,612
$14.45 P/Share
|
|
Jul 11
2025
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,884
-1.84%
|
$222,376
$14.51 P/Share
|
|
Jun 13
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,366
-10.06%
|
$159,124
$14.6 P/Share
|
|
Jun 12
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,348
+5.32%
|
$6,348
$1.08 P/Share
|
|
May 14
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,366
-9.63%
|
$170,490
$15.29 P/Share
|
|
May 12
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+5.1%
|
$6,349
$1.08 P/Share
|
|
Apr 14
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,366
-4.7%
|
$159,124
$14.26 P/Share
|
|
Apr 14
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,348
+4.91%
|
$6,348
$1.08 P/Share
|
|
Apr 11
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
10,757
-4.76%
|
$129,084
$12.06 P/Share
|
|
Apr 11
2025
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,319
-1.75%
|
$183,828
$12.19 P/Share
|
|
Apr 01
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
55,771
-11.93%
|
$836,565
$15.93 P/Share
|
|
Apr 01
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,606
+0.92%
|
$1,606
$1.08 P/Share
|
|
Mar 13
2025
|
Brian Taylor Slingsby Director |
BUY
Open market or private purchase
|
Indirect |
259,259
+2.83%
|
$3,370,367
$13.5 P/Share
|
Last 12 Months Summary
Buy / Acquisition
2.88M
Shares
From
5
Insiders
| Open market or private purchase | 2.76M shares |
|---|---|
| Exercise of conversion of derivative security | 120K shares |
Sell / Disposition
325K
Shares
From
3
Insiders
| Open market or private sale | 325K shares |
|---|